Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01192828 · ClinicalTrials.gov registry record · Phase 1

Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine

A Phase 1 study, sponsored by University of Colorado, Denver.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target

NCT01192828 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01192828, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target

Study Summary

Cystathionine beta-synthase deficiency is an inherited disease that results in elevation of a substance called homocysteine (Hcy) in blood and urine. Individuals with this disorder have a very high risk for developing blood clots and are at risk for developing eye and bone abnormalities. Current treatments are generally difficult to follow and can fail. Development of additional therapies has been limited by lack of understanding of how the disease works. The purpose of this study is to see if oxidative stress and inflammation are involved in the disease process and if short-term supplementation with taurine is an effective treatment. Funding source: FDA.

Interventions

  • DRUG taurine

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2010-01
Est. Completion 2017-12
Phase Phase 1

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT01192828

The ClinicalTrials.gov registry entry for NCT01192828 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which taurine is the first listed.

NCT01192828 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01192828 about?

NCT01192828 is a clinical study titled "Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine". Cystathionine beta-synthase deficiency is an inherited disease that results in elevation of a substance called homocysteine (Hcy) in blood and urine. Individuals with this disorder have a very high risk for developing blood clots and are at risk for developing eye and bone abnormalities. Current tre...

What is the current status of trial NCT01192828?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2010-01. Estimated completion is 2017-12.

What interventions are being tested in trial NCT01192828?

The interventions under investigation include: taurine (DRUG).

Who is sponsoring clinical trial NCT01192828?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.